Theravance Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Theravance Biopharma

18/02/2023 01:16

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
21 (estimated). 
    * The George Town Grand Cayman-based  company is expected to
report  a 5.2% increase in revenue to $15.724 million from
$14.95 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $12​, above​ its last closing price of $10.44.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.21       -0.18      -0.21     Missed  -15.1
 Jun. 30 2022  0.09        0.11       -0.09     Missed  -182.6
 Mar. 31 2022  -0.11       -0.11      -0.22     Missed  -107.5
                                                        ​
 Dec. 31 2021  -0.32       -0.33      -0.43     Missed  -29.7
 ​​Sep.        -0.56       -0.56      -0.48     Beat    14.1
 30 2021                                                
 Jun. 30 2021  -1.02       -1.00      -0.80     Beat    19.9​
 Mar. 31 2021  -1.05       -1.05      -1.24     Missed  -18.3
 Dec. 31 2020  -1.02       -1.02      -0.92     Beat    9.4
 This summary was machine generated February 18 at 01:16 GMT. 
All figures in US dollars  unless otherwise stated